Siegel, Craig,Bastos, Cecilia M,Harris, David J,Dios, Angeles,Lee, Edward,Silva, Richard,Cuff, Lisa M,Levine, Mikaela,Celatka, Cassandra,Vinick, Frederic,Jozefiak, Thomas,Xiang, Yibin,Kane, John,Liao,
申请号：
HK13112541.4
公开号：
HK1185076B
申请日:
2013.11.07
申请国别(地区):
HK
年份:
2017
代理人:
摘要：
A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes； renal hypertrophy or hyperplasia associated with diabetic nephropathy； Tay-Sachs； Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-±, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
